Pillstats
Rx only · Injection, Solution · Subcutaneous

Fondaparinux Sodium

Brands: Arixtra · Fondaparinux Sodium

4 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US20 NDCs
4 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCB01AX05
RxCUI (US)321208
US makers4 labelers
Packages32
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 15 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$11.80$23.60$35.40$47.20Jan 2025Feb 2026Jul 2026
$36.592
Latest avg · Jul 22, 2026
+75%
Since Jan 22, 2025
4
Active US suppliers
50%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

2304606909202025 Q12025 Q22025 Q32025 Q42026 Q1
720
Rx · 2026 Q1
12K
Units dispensed
+10%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it4 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Mylan Institutional LLCunknown8SUPPLYING
Italfarmaco SpAunknown8SUPPLYING
Eugia US LLCunknown8SUPPLYING
Zydus Pharmaceuticals USA Inc.unknown8SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Sep 30, 2022
    RECALLRecall (Class II): Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Distributed by: AuroMedics Pharm…

    Subpotent Drug: Out of specification for assay — Recalling firm: AuroMedics Pharma LLC — Nationwide in the USA